Matthew Crawford, PhD, of the University of Virginia, and Mario Danek of Qnovia explain what pharmacists can do now and what may come next.
|Articles|January 2, 2006
New growth hormone approved for short kids
Advertisement
Insmed Inc. has received the green light from the FDA for iPlex (mecasermin rinfabate [rDNA origin] injection) for the treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. According to the Richmond, Va., firm, iPlex is the only approved once-daily IGF-1 replacement therapy available to treat children with short stature.
Advertisement
Related to this article
The inquiry puts audit practices, including how pharmacies are selected for audit, proportionality, and pharmacy advocacy in focus.
Nolla Derm’s overseeing physician, Zaid Fadul, MD, FS, FAAFP, discusses the revolutionary AI technology that could transform how health care conducts prescribing practices.
As COVID-19 vaccine guidance shifts, new data suggest vaccinated patients face no greater clot or death risk than with other respiratory infections.
Alyssa Eisenberg, PharmD, explores technology’s emerging role in the health care environment and how the pharmacist of the future’s day-to-day tasks might evolve.
In the final portion of our discussion with Kimberly Kue-Tsemo, PharmD, she explores the key developments that could be the most significant push toward reducing pharmacy deserts.
In the second part of our interview with a collection of pharmacists from various backgrounds, they delve into the current developments highlighting the future of the profession.
Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.
Advertisement
Advertisement
Trending on Drug Topics
1
COVID-19 Vaccine Lowers Venous Thromboembolism, Mortality Risk
2
PBMs Must Now Disclose Fees to Employer Plans Under Final DOL Rule
3
AI Prescribing Pilot Places Pharmacists as Final Link in Care
4
PBM Audit Practices Under Scrutiny: What the House Inquiry Means for Independent Pharmacies
5